Related Experiment Video

Updated: Aug 20, 2025

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

18.9K

Insulin Pump Therapy Efficacy and Key Factors Influencing Adherence in Pediatric Population-A Narrative Review

Laura Mihaela Trandafir1,2, Stefana Maria Moisa1,2, Mihaela Victoria Vlaiculescu3

  • 1Pediatrics Department, University of Medicine and Pharmacy "Grigore T. Popa", 700115 Iasi, Romania.

Medicina (Kaunas, Lithuania)
|November 24, 2022
PubMed

Insights

Improving pediatric adherence to insulin pump therapy is crucial for better glycemic control. Addressing factors affecting adherence, like communication and support, enhances diabetes management in children.

Area of Science:

  • Pediatric Endocrinology
  • Diabetes Management
  • Medical Adherence Research

Background:

  • Insulin pump therapy is a key treatment for type 1 diabetes in children.
  • Optimizing adherence to insulin pump therapy is essential for effective disease management.
  • Understanding factors influencing adherence is critical for improving patient outcomes.

Purpose of the Study:

  • To review the current state of pediatric adherence to insulin pump therapy.
  • To identify and minimize factors negatively impacting adherence in the pediatric population.
  • To emphasize the importance of adherence for juvenile diabetes management.

Main Methods:

  • Systematic literature search of PubMed, Embase, and Science Direct databases.
  • Utilized keywords: adherence, pump insulin therapy, children, pediatric population, type 1 diabetes, and synonyms.
  • Evaluated articles focusing on factors affecting insulin pump adherence in children.

Main Results:

  • Better adherence to diabetes management correlates with improved glycemic control.
  • Identified numerous variables that hinder adherence to insulin pump therapy regimens.
  • Key factors for improved adherence include: effective provider-patient communication (telehealth), continuous education, family support, and societal assistance.

Conclusions:

  • Obstacles to optimal insulin pump adherence in young patients present intervention opportunities.
  • Improving adherence can lead to enhanced glycemic control.
  • Successfully addressing adherence challenges significantly improves the quality of life for pediatric patients with type 1 diabetes.

Keywords:
adherencecontinuous subcutaneous insulin infusioninsulin pump therapypediatric populationtype 1 diabetes mellitus

More Related Videos

Using Continuous Data Tracking Technology to Study Exercise Adherence in Pulmonary Rehabilitation09:42

Using Continuous Data Tracking Technology to Study Exercise Adherence in Pulmonary Rehabilitation

Published on: November 8, 2013

13.6K
Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform07:13

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

Published on: April 12, 2021

4.4K

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
226
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
250
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.9K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
328
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
1.4K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
383